0001209191-23-021412.txt : 20230328 0001209191-23-021412.hdr.sgml : 20230328 20230328164554 ACCESSION NUMBER: 0001209191-23-021412 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230324 FILED AS OF DATE: 20230328 DATE AS OF CHANGE: 20230328 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Feingold Jay CENTRAL INDEX KEY: 0001885838 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-40881 FILM NUMBER: 23770206 MAIL ADDRESS: STREET 1: C/O PYXIS ONCOLOGY, INC. STREET 2: 35 CAMBRIDGEPARK DRIVE CITY: CAMBRIDGE STATE: MA ZIP: 02140 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Pyxis Oncology, Inc. CENTRAL INDEX KEY: 0001782223 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 831160910 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 35 CAMBRIDGE PARK DRIVE CITY: CAMBRIDGE STATE: MA ZIP: 02140 BUSINESS PHONE: (617) 221-9059 MAIL ADDRESS: STREET 1: 35 CAMBRIDGE PARK DRIVE CITY: CAMBRIDGE STATE: MA ZIP: 02140 4 1 doc4.xml FORM 4 SUBMISSION X0407 4 2023-03-24 0 0001782223 Pyxis Oncology, Inc. PYXS 0001885838 Feingold Jay C/O PYXIS ONCOLOGY, INC. 150 CAMBRIDGEPARK DRIVE CAMBRIDGE MA 02140 0 1 0 0 Chief Medical Officer 0 Common Stock 2023-03-24 4 A 0 209803 0.00 A 730345 D Stock Option (Right to buy) 8.71 2023-03-24 4 D 0 157257 D 2031-09-12 Common Stock 157257 0 D Stock Option (Right to buy) 8.71 2023-03-24 4 D 0 17517 D 2031-09-14 Common Stock 17517 0 D Stock Option (Right to buy) 2.21 2023-03-24 4 A 0 157257 A 2031-09-12 Common Stock 157257 157257 D Stock Option (Right to buy) 2.21 2023-03-24 4 A 0 17517 A 2031-09-14 Common Stock 17517 17517 D Represents restricted stock units that vest 25% on March 24, 2024, and then in 36 substantially-equal monthly installments thereafter, subject to the reporting person's continued employment through the applicable vesting date. In accordance with the terms of the Pyxis Oncology, Inc. 2019 Equity and Incentive Plan (the "Plan"), the Board of Directors of Pyxis Oncology, Inc. approved a stock option repricing pursuant to which option awards granted under the Plan were amended to reduce the exercise price to $2.21 per share, the closing stock price on the date of Board approval. Except for the modified exercise price, all other terms and conditions of each of the option awards will continue as set forth in the Plan and the applicable award agreements. These stock options vested 25% on the first anniversary of the September 13, 2021 grant date, and then vests in 36 substantially-equal monthly installments thereafter, subject to the reporting person's continued employment through the applicable vesting date. These stock options vested 25% on the first anniversary of the closing of the Issuer's initial public offering, and then vests in 36 substantially-equal monthly installments thereafter, subject to the reporting person's continued employment through the applicable vesting date. /s/ Pamela Connealy, Attorney-in-Fact for Jay Feingold 2023-03-28